Skip to content
Screener

Johnson & Johnson JNJ PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — Percent Change (as a percent)

Similar metrics at other companies

Healthcare Services Group logo
HCSGPercent of liabilities (as a percent)
24.8%-0.6pp
Calix logo
CALXPercent of historical volatility (as a percent)
50%0.0pp
Calix logo
CALXPercent of implied volatility (as a percent)
50%0.0pp
Equifax logo
EFXVerification Services — Change in revenue (as a percent)
7%-3.0pp
Equifax logo
EFXEmployer Services — Change in revenue (as a percent)
3%+2.1pp
Equifax logo
EFXEurope — Change in revenue (as a percent)
2%-10.0pp

Other financials

Income statement

See full
Revenue$25.3B+6.6%
Gross profit$17.3B+7.1%
Operating income$7.1B+7.4%
Net income$5.5B-0.1%
EPS (diluted)$2.27-0.9%

Balance sheet

See full
Cash & equivalents$20.4B+9.9%
Total debt$49.0B-3.4%
Total equity$85.0B+8.3%
Total assets$201.06B+4.0%

Cash flow

See full
Operating cash flow$8.6B+122%
CapEx$1.3B+26.7%
Free cash flow$7.3B+157%

Valuation

See full
Market cap$620.77B+51.1%
Enterprise value$649.38B+46.6%
P/E29.5×+11.4×
P/S6.3×+1.8×

Profitability

See full
Gross margin67.9%0.0pp
Operating margin26.5%+2.8pp
Net margin21.5%-3.5pp
FCF margin22.7%+2.2pp

Returns & leverage

See full
Return on equity25.7%-4.5pp
Debt / equity0.6×-0.1×
Current ratio1.1×+0.1×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept jnj:PercentageChangeInSalesBySegmentOfBusiness.

The source filing: Johnson & Johnson’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000200406-26-000153
(Dollars in Millions)Fiscal Second Quarter Ended / June 28,2026Fiscal Second Quarter Ended / June 29,2025Fiscal Second Quarter Ended / Percent ChangeFiscal Six Months Ended / June 28,2026Fiscal Six Months Ended / June 29,2025Fiscal Six Months Ended / Percent Change
International2912679.259253710.3
Worldwide8277687.61,6601,5407.8
SPINE, SPORTS & OTHER
U.S.4234220.28108100.0
International3173054.06245886.1
Worldwide7407271.81,4341,3982.6
TOTAL MEDTECH
U.S.4,5544,3833.99,0138,5964.8

Item 1 — Financial statements

FAQ

What is Johnson & Johnson's PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — percent change (as a percent)?
Johnson & Johnson (JNJ) reported PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — percent change (as a percent) of -6.3% in Q2 2026.
How has Johnson & Johnson's PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — percent change (as a percent) changed year-over-year?
Johnson & Johnson's PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — percent change (as a percent) increased by 33.0% year-over-year, from -9.4% to -6.3%.
What does PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — percent change (as a percent) mean?
This metric measures the period-over-period growth rate of revenue derived from a specific portfolio of HIV antiviral medications. It provides a normalized view of the product line's momentum, stripping away absolute scale to highlight acceleration or deceleration in sales performance. This is a key indicator for evaluating the commercial trajectory of the company's mature pharmaceutical assets.

Ask your AI about Johnson & Johnson's prezista/prezcobix/rezolsta/symtuza — percent change (as a percent).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude